Drugs / MG-O-1002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05390840 | Aug 2022 → Mar 2024 | age-related macular degeneration | Theratocular Biotek Co. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MG-O-1002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05390840 ↗ |
| Route | Topical | “Route of administration: topical ocular” NCT05390840 ↗ |